Leap Therapeutics （LPTX.US）Stock Market Quotes
November 12,$Leap Therapeutics （LPTX.US）$ surged as much as 466.85% and is now up 407.42% at $2.22, with trading volume reaching $690 million.
1、Leap Therapeutics （Nasdaq: LPTX） shares rose 12.92% to $2.31. The market capitalization of its outstanding shares stands at $24.7 million.
2、Leap Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 320.57%
3、Leap Therapeutics Inc: May Offer, Sell Shares of Common Stock of up to $200 Mln From Time to Time
Company Performance
Cypherpunk Technologies （Formerly Leap Therapeutics） Reports Third Quarter 2025 Financial Results
Leap Therapeutics Q3 Net Income USD -3.3 Million
Leap Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
Leap Therapeutics Rebrands and Acquires Zcash Tokens
Leap Therapeutics （ LPTX ） just unveiled an update.
On November 11, 2025, Cypherpunk Technologies Inc. announced a series of strategic changes, including a rebranding from Leap Therapeutics and the introduction of a digital asset treasury strategy. The company has used $50 million from a private placement led by Winklevoss Capital to acquire 203,775 Zcash tokens, aiming to enhance shareholder value through this investment. Additionally, Khing Oei and William McEvoy were appointed to the board, with McEvoy also serving as Chief Investment Officer, marking a significant leadership expansion. The company also announced a change in its Nasdaq ticker symbol to ‘CYPH’ effective November 13, 2025, reflecting its new strategic direction.
The most recent analyst rating on LPTX stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.
Spark’s Take on LPTX Stock
According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.
Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.
Leap Therapeutics, Inc. （LPTX） Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia （excluding Japan）， Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.